Karpathy R C, Firth G A, Tannock G A
Intervet Australia Pty Ltd, Vaccine Production Laboratory, PO Box 285, Beresfield, New South Wales 2322.
Aust Vet J. 2003 Apr;81(4):222-5. doi: 10.1111/j.1751-0813.2003.tb11475.x.
To demonstrate the safety and efficacy of the Marek's Disease Virus-1 vaccine (strain BH 16) from field studies in comparison with the CVI 988 Rispens vaccine currently available in Australia.
A small field trial was carried out on nine breeder flocks and a larger trial on 21 breeder flocks. All chickens were obtained from a commercial hatchery and each was vaccinated at hatch with cell-associated Herpes Virus of Turkeys vaccine. A group of chickens vaccinated with BH 16 vaccine was placed in one shed per property and the remainder were vaccinated with the Rispens vaccine and placed in the remaining sheds. At 25, 30, 35, and 40 weeks after hatch, the field veterinarian or farm manager examined all birds dying on two consecutive days in the designated placement sheds.
In the small trial there was a significantly lower incidence of MD in birds vaccinated with the MDV-1 vaccine compared with the Rispens vaccine (P < 0.001). In a larger trial there was no difference in the incidence of MD between the treatment groups, due possibly to a lower rate of natural challenge. Egg production results and average weekly mortality results for both groups were similar.
The present study describes an attenuated type 1 MD vaccine which is at least equivalent to a vaccine derived from the CVI 988 Rispens strain in terms of safety and efficacy when used in combination with HVT vaccine.
通过现场研究，与澳大利亚目前可用的CVI 988 Rispens疫苗相比，证明马立克氏病病毒1型疫苗（BH 16株）的安全性和有效性。
对9个种鸡群进行了小型现场试验，对21个种鸡群进行了更大规模的试验。所有鸡均从商业孵化场获得，每只鸡在孵化时接种与细胞相关的火鸡疱疹病毒疫苗。一组接种BH 16疫苗的鸡被放置在每个养殖场的一个鸡舍中，其余的接种Rispens疫苗并放置在其余鸡舍中。在孵化后25、30、35和40周，现场兽医或农场经理检查了指定放置鸡舍中连续两天死亡的所有鸡。
在小型试验中，与Rispens疫苗相比，接种MDV-1疫苗的鸡群中MD发病率显著较低（P < 0.001）。在更大规模试验中，治疗组之间MD发病率没有差异，可能是由于自然感染率较低。两组的产蛋结果和平均每周死亡率结果相似。
本研究描述了一种1型减毒MD疫苗，当与HVT疫苗联合使用时，其安全性和有效性至少与源自CVI 988 Rispens株的疫苗相当。
